Articles

UofT Libraries is getting a new library services platform in January 2021.
Learn more about the change.

Search Articles

Advanced search
Help

Catalogue

Articles

Databases

X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
science & technology (3213) 3213
life sciences & biomedicine (3004) 3004
animals (2432) 2432
humans (2121) 2121
mice (2022) 2022
female (1565) 1565
immunology (1458) 1458
biological and medical sciences (1112) 1112
male (1103) 1103
medical sciences (936) 936
interleukin-12 - immunology (814) 814
cytokines (781) 781
interleukin-12 - metabolism (772) 772
mice, inbred c57bl (767) 767
interleukin-12 - genetics (766) 766
mice, inbred balb c (734) 734
interleukin-12 - therapeutic use (634) 634
immunotherapy (617) 617
interleukin-12 (589) 589
medicine, research & experimental (560) 560
research & experimental medicine (560) 560
oncology (552) 552
adult (535) 535
dendritic cells - immunology (517) 517
interleukin-12 - biosynthesis (505) 505
cells, cultured (482) 482
middle aged (474) 474
dendritic cells (471) 471
interleukin 12 (397) 397
il-12 (386) 386
pharmacology. drug treatments (374) 374
th1 cells - immunology (359) 359
abridged index medicus (357) 357
fundamental and applied biological sciences. psychology (350) 350
health aspects (350) 350
disease models, animal (346) 346
t cells (340) 340
research (336) 336
cell biology (324) 324
interferon-gamma - metabolism (320) 320
tumors (319) 319
interleukins (313) 313
interferon-gamma - biosynthesis (310) 310
cancer (309) 309
cell line, tumor (307) 307
t-lymphocytes - immunology (300) 300
interleukin-12 - blood (292) 292
infectious diseases (291) 291
interleukin-12 - pharmacology (286) 286
inflammation (283) 283
research article (283) 283
immune system (276) 276
immune response (274) 274
lymphocytes (272) 272
biotechnology & applied microbiology (270) 270
analysis (268) 268
microbiology (266) 266
gene expression (265) 265
interferon-gamma - immunology (265) 265
killer cells, natural - immunology (257) 257
mice, knockout (256) 256
care and treatment (254) 254
flow cytometry (251) 251
gene therapy (250) 250
aged (249) 249
enzyme-linked immunosorbent assay (248) 248
pharmacology & pharmacy (235) 235
biochemistry & molecular biology (229) 229
medicine (228) 228
interleukin-12 - administration & dosage (226) 226
dendritic cells - metabolism (224) 224
cd8-positive t-lymphocytes - immunology (222) 222
time factors (219) 219
antibodies, monoclonal - therapeutic use (218) 218
antigens (218) 218
antineoplastic agents (217) 217
cd4-positive t-lymphocytes - immunology (213) 213
lymphocytes t (212) 212
genetics & heredity (207) 207
treatment outcome (207) 207
proteins (206) 206
rodents (204) 204
tumor cells, cultured (203) 203
dendritic cells - drug effects (201) 201
genetic therapy - methods (199) 199
science & technology - other topics (199) 199
tumor necrosis factor-alpha - metabolism (197) 197
genetic aspects (190) 190
interleukin-12 - antagonists & inhibitors (190) 190
interleukin-10 - metabolism (187) 187
multidisciplinary sciences (185) 185
t-lymphocytes, cytotoxic - immunology (184) 184
physiological aspects (181) 181
vaccines (180) 180
lymphocyte activation (179) 179
cytokines - metabolism (178) 178
infections (173) 173
cytokines - biosynthesis (170) 170
dermatology (168) 168
aids/hiv (167) 167
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (3781) 3781
Chinese (49) 49
Japanese (34) 34
Spanish (9) 9
Polish (7) 7
German (6) 6
Russian (5) 5
French (4) 4
Turkish (3) 3
Portuguese (2) 2
Danish (1) 1
Finnish (1) 1
Hungarian (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


1. Full Text Efficacy and safety of the anti-IL-12/23 p40 monoclonal antibody, ustekinumab, in patients with active psoriatic arthritis despite conventional non-biological and biological anti-tumour necrosis factor therapy: 6-month and 1-year results of the phase 3, multicentre, double-blind, placebo-controlled, randomised PSUMMIT 2 trial
by Ritchlin, Christopher and Rahman, Proton and Kavanaugh, Arthur and McInnes, Iain B and Puig, Lluis and Li, Shu and Wang, Yuhua and Shen, Yaung-Kaung and Doyle, Mittie K and Mendelsohn, Alan M and Gottlieb, Alice B and PSUMMIT 2 Study Grp and PSUMMIT 2 Study Group and on behalf of the PSUMMIT 2 Study Group
Annals of the rheumatic diseases, ISSN 0003-4967, 06/2014, Volume 73, Issue 6, pp. 990 - 999
Life Sciences & Biomedicine | Rheumatology | Science & Technology | Certolizumab Pegol | Humans | Middle Aged | Ustekinumab | Antibodies, Monoclonal - therapeutic use | Male | Immunoglobulin Fab Fragments - therapeutic use | Methotrexate - therapeutic use | Polyethylene Glycols - therapeutic use | Interleukin-12 Subunit p40 - antagonists & inhibitors | Receptors, Tumor Necrosis Factor - therapeutic use | Etanercept | Infliximab | Arthritis, Psoriatic - drug therapy | Treatment Failure | Adult | Female | Antirheumatic Agents - therapeutic use | Severity of Illness Index | Antibodies, Monoclonal, Humanized - therapeutic use | Psoriasis - drug therapy | Double-Blind Method | Immunoglobulin G - therapeutic use | Treatment Outcome | Cross-Over Studies | Adalimumab | Tumor Necrosis Factor-alpha - antagonists & inhibitors | Clinical trials | Care and treatment | Usage | Psoriatic arthritis | Heart attacks | Tuberculosis | Psoriasis | Mortality | Response rates | Gangrene | Tumor necrosis factor-TNF | Arthritis | Pharmaceutical industry | Drug dosages | Quality of life | Index Medicus | Anti-TNF | Clinical and Epidemiological Research | 1506 | Spondyloarthritis | Psoriatic Arthritis
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
2. Full Text Special Article: 2018 American College of Rheumatology/National Psoriasis Foundation Guideline for the Treatment of Psoriatic Arthritis
by Singh, Jasvinder A and Guyatt, Gordon and Ogdie, Alexis and Gladman, Dafna D and Deal, Chad and Deodhar, Atul and Dubreuil, Maureen and Dunham, Jonathan and Husni, M. Elaine and Kenny, Sarah and Kwan-Morley, Jennifer and Lin, Janice and Marchetta, Paula and Mease, Philip J and Merola, Joseph F and Miner, Julie and Ritchlin, Christopher T and Siaton, Bernadette and Smith, Benjamin J and Van Voorhees, Abby S and Jonsson, Anna Helena and Shah, Amit Aakash and Sullivan, Nancy and Turgunbaev, Marat and Coates, Laura C and Gottlieb, Alice and Magrey, Marina and Nowell, W. Benjamin and Orbai, Ana-Maria and Reddy, Soumya M and Scher, Jose U and Siegel, Evan and Siegel, Michael and Walsh, Jessica A and Turner, Amy S and Reston, James
Arthritis & rheumatology (Hoboken, N.J.), ISSN 2326-5191, 01/2019, Volume 71, Issue 1, pp. 5 - 32
Life Sciences & Biomedicine | Rheumatology | Science & Technology | Occupational Therapy | Arthritis, Psoriatic - epidemiology | Glucocorticoids - therapeutic use | Humans | Immunosuppressive Agents - therapeutic use | Antibodies, Monoclonal - therapeutic use | Infliximab - therapeutic use | Inflammatory Bowel Diseases - epidemiology | Exercise | Societies, Medical | Interleukin-23 - antagonists & inhibitors | Interleukin-12 - antagonists & inhibitors | Physical Therapy Modalities | Pyrroles - therapeutic use | Antirheumatic Agents - therapeutic use | Antibodies, Monoclonal, Humanized - therapeutic use | Enthesopathy - therapy | Comorbidity | Spondylitis - therapy | Evidence-Based Medicine | Ustekinumab - therapeutic use | Adalimumab - therapeutic use | Interleukin-17 - antagonists & inhibitors | Anti-Inflammatory Agents, Non-Steroidal - therapeutic use | Piperidines - therapeutic use | Pyrimidines - therapeutic use | Weight Loss | Abatacept - therapeutic use | Diabetes Mellitus - epidemiology | Diabetes Mellitus - therapy | Inflammatory Bowel Diseases - therapy | Tumor Necrosis Factor-alpha - antagonists & inhibitors | Arthritis, Psoriatic - therapy | Etanercept - therapeutic use | Smoking Cessation | Index Medicus | Abridged Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
3. Full Text The immunocytokine NHS-IL12 as a potential cancer therapeutic
by Fallon, Jonathan and Tighe, Robert and Tighe, Robert and Kradjian, Giorgio and Guzman, Wilson and Bernhardt, Anna and Neuteboom, Berend and Neuteboom, Berend and Lan, Yan and Sabzevari, Helen and Schlom, Jeffrey and Greiner, John W and Greiner, John W
Oncotarget, ISSN 1949-2553, 2014, Volume 5, Issue 6, pp. 1869 - 1884
Immunocytokine | Tumor necrosis therapy | T cells | Immunotherapy | Interleukin-12 | Oncology | Life Sciences & Biomedicine | Science & Technology | Cell Biology | Recombinant Fusion Proteins - immunology | Recombinant Fusion Proteins - pharmacology | Humans | Recombinant Fusion Proteins - therapeutic use | Macaca fascicularis | Interferon-gamma - metabolism | Indoles - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - pharmacology | CD8-Positive T-Lymphocytes | Cancer Vaccines - therapeutic use | Immunoglobulin G - immunology | Pyrroles - administration & dosage | Protein Engineering | Immunoglobulin G - pharmacology | Female | Interleukin-12 - therapeutic use | Interleukin-12 - pharmacology | Immunomodulation | Cancer Vaccines - administration & dosage | Mice, Inbred C57BL | Neoplasms, Experimental - therapy | Immunoglobulin G - therapeutic use | Survival Rate | Tumor Burden | Antineoplastic Combined Chemotherapy Protocols - immunology | Taxoids - administration & dosage | Animals | Membrane Glycoproteins - therapeutic use | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Lymphocyte Activation - drug effects | Interleukin-12 - immunology | Cell Line, Tumor | Mice | Mice, Inbred BALB C | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
4. Full Text Interleukin-12: Biological Properties and Clinical Application
by Michele Del Vecchio and Emilio Bajetta and Stefania Canova and Michael T. Lotze and Amy Wesa and Giorgio Parmiani and Andrea Anichini
Clinical Cancer Research, ISSN 1078-0432, 08/2007, Volume 13, Issue 16, pp. 4677 - 4685
T lymphocytes | tumor immunity | dendritic cells | Interleukin-12 | angiogenesis | Life Sciences & Biomedicine | Oncology | Science & Technology | Biological and medical sciences | Medical sciences | Antineoplastic agents | Pharmacology. Drug treatments | Genetic Therapy | Adjuvants, Immunologic - pharmacology | Interleukin-12 - genetics | Humans | Vaccination | Interleukin-12 - physiology | Angiogenesis Inhibitors - pharmacology | Antibodies, Monoclonal - therapeutic use | Antineoplastic Agents - therapeutic use | Immunity, Innate | Neoplasms - drug therapy | Animals | Angiogenesis Inhibitors - therapeutic use | Interleukin-12 - therapeutic use | Interleukin-12 - pharmacology | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
5. Full Text New Interleukin-23 Pathway Inhibitors in Dermatology
: Ustekinumab, Briakinumab, and Secukinumab
by Kurzeja, Marta and Rudnicka, Lidia and Olszewska, Malgorzata
American journal of clinical dermatology, ISSN 1175-0561, 4/2011, Volume 12, Issue 2, pp. 113 - 125
Pharmacotherapy | Medicine & Public Health | Pharmacology/Toxicology | Dermatology | Research-and-development | Interleukin-17-receptor- antagonists, therapeutic use | Ustekinumab, adverse reactions | AMG-827, therapeutic use | Briakinumab, therapeutic use | Psoriatic-arthritis, treatment | Interleukin-23-inhibitors, therapeutic use | LY-2439821, therapeutic use | Interleukin-12-inhibitors, therapeutic use | LY-2525623, therapeutic use | Psoriasis, treatment | Ustekinumab, therapeutic use | Apilimod, therapeutic use | Secukinumab, therapeutic use | Life Sciences & Biomedicine | Science & Technology | Biological and medical sciences | Medical sciences | Psoriasis - immunology | Psoriasis - drug therapy | Antibodies, Monoclonal - pharmacology | Humans | Antibodies, Monoclonal - adverse effects | Ustekinumab | Dermatologic Agents - adverse effects | Interleukin-23 - immunology | Drug Delivery Systems | Antibodies, Monoclonal, Humanized | Animals | Arthritis, Psoriatic - immunology | Arthritis, Psoriatic - drug therapy | Interleukin-12 - immunology | Dermatologic Agents - pharmacology | Physiological aspects | Research | Interleukins | Psoriasis | Drug therapy | Risk factors
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
6. Targeting Specific Immunologic Pathways in Crohn's Disease
by Ramos, Guilherme Piovezani and Faubion, William A and Papadakis, Konstantinos A
Gastroenterology clinics of North America, ISSN 0889-8553, 09/2017, Volume 46, Issue 3, pp. 577 - 588
Inflammatory bowel diseases | Crohn's disease | Immunology | Target therapy | Gastroenterology & Hepatology | Life Sciences & Biomedicine | Science & Technology | Antibodies, Monoclonal, Humanized - therapeutic use | Humans | Th1 Cells - immunology | Cell Adhesion Molecules - metabolism | Crohn Disease - immunology | Integrins - metabolism | Ustekinumab - therapeutic use | Interleukin-23 - immunology | Cell Movement - immunology | Leukocytes - immunology | Signal Transduction - immunology | Janus Kinase Inhibitors - therapeutic use | Endothelium, Vascular - metabolism | Piperidines - therapeutic use | Pyrimidines - therapeutic use | Crohn Disease - drug therapy | Natalizumab - therapeutic use | Gastrointestinal Agents - therapeutic use | Interleukin-12 - immunology | Th17 Cells - immunology | Janus Kinases - immunology | Interleukin-12 Subunit p40 - immunology | Pyrroles - therapeutic use | Immunologic Factors - therapeutic use | Index Medicus
Journal Article
Details down arrow
7. Full Text Comparison of Ustekinumab and Etanercept for Moderate-to-Severe Psoriasis
by Griffiths, Christopher E.M and Strober, Bruce E and van de Kerkhof, Peter and Ho, Vincent and Fidelus-Gort, Roseanne and Yeilding, Newman and Guzzo, Cynthia and Xia, Yichuan and Zhou, Bei and Li, Shu and Dooley, Lisa T and Goldstein, Neil H and Menter, Alan and ACCEPT Study Grp and ACCEPT Study Group
The New England journal of medicine, ISSN 0028-4793, 01/2010, Volume 362, Issue 2, pp. 118 - 128
Medicine, General & Internal | Life Sciences & Biomedicine | General & Internal Medicine | Science & Technology | Biological and medical sciences | General aspects | Medical sciences | Dermatology | Psoriasis. Parapsoriasis. Lichen | Severity of Illness Index | Psoriasis - drug therapy | Humans | Immunosuppressive Agents - therapeutic use | Middle Aged | Immunologic Factors - administration & dosage | Immunoglobulin G - therapeutic use | Ustekinumab | Antibodies, Monoclonal - therapeutic use | Male | Receptors, Tumor Necrosis Factor - administration & dosage | Immunoglobulin G - administration & dosage | Receptors, Tumor Necrosis Factor - therapeutic use | Antibodies, Monoclonal, Humanized | Etanercept | Antibodies, Monoclonal - administration & dosage | Interleukin-23 - antagonists & inhibitors | Interleukin-12 - antagonists & inhibitors | Adult | Female | Immunosuppressive Agents - administration & dosage | Tumor Necrosis Factor-alpha - antagonists & inhibitors | Immunologic Factors - therapeutic use | Dosage and administration | Psoriasis | Comparative analysis | Drug therapy | Fees & charges | Cytokines | Stock options | Laboratories | Research & development--R&D | Equity | Interleukin 23 | Interleukin 12 | Tumor necrosis factor-α | Light therapy | Patients | Studies | Tumor necrosis factor-TNF | Index Medicus | Abridged Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
8. Full Text The Expanding Therapeutic Armamentarium for Inflammatory Bowel Disease: How to Choose the Right Drug[s] for Our Patients?
by Hinyckx, Pieter and Vande Casteele, Niels and Novak, Gregor and Khanna, Reena and D'Haens, Geert and Sandborn, William J and Danese, Silvio and Jairath, Vipul and Feagan, Brian G
Journal of Crohn's and colitis, ISSN 1873-9946, 2018, Volume 12, Issue 1, pp. 105 - 119
Inflammatory bowel disease | Therapy | TNF antagonists | Sphingosine-1 phosphate | IL-23 antagonists | JAK inhibitors | Smad7 | Pipeline | Gastroenterology & Hepatology | Life Sciences & Biomedicine | Science & Technology | Antibodies, Monoclonal, Humanized - adverse effects | Immunoglobulins | Antibodies, Monoclonal, Humanized - therapeutic use | Smad7 Protein - antagonists & inhibitors | Humans | Immunosuppressive Agents - therapeutic use | Protein Kinase Inhibitors - adverse effects | Adrenal Cortex Hormones - therapeutic use | Molecular Targeted Therapy | Janus Kinases - antagonists & inhibitors | Algorithms | Interleukin-23 - antagonists & inhibitors | Protein Kinase Inhibitors - therapeutic use | Crohn Disease - drug therapy | Interleukin-12 - antagonists & inhibitors | Vascular Cell Adhesion Molecule-1 - antagonists & inhibitors | Colitis, Ulcerative - drug therapy | Drug Therapy, Combination | Mucoproteins - antagonists & inhibitors | Integrins - antagonists & inhibitors | Tumor Necrosis Factor-alpha - antagonists & inhibitors | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights